Quantum Blue OverviewApplicationsBenefitsCase StudiesVideosPostersPublicationsQuantum Blue Overview In 2013 NICE published the DG11 guidance supporting the use of calprotectin as a cost-effective method to differentiate between IBD and IBS. Since that time, the level of testing within laboratories has increased significantly and BÜHLMANN has expanded its product portfolio to assist with evolving hospital requirements. BÜHLMANN offers
Continue Reading
Faecal calprotectin increases the diagnostic yield in patients with suspected small bowel disease – a multicenter retrospective cohort studyFaecal calprotectin testing increases the diagnostic yield of small bowel capsule endoscopy and may help identify patients at risk of small bowel disease. Abo El Ela et al. Swiss Medical Weekly March 2023 Faecal Calprotectin in Primary
Continue Reading
Calprotectin is a protein biomarker that is present in the faeces when intestinal inflammation occurs. Faecal calprotectin testing is helping to improve patient care and save money for the NHS. It prevents the need for unnecessary endoscopy procedures on many patients by screening out those with Irritable Bowel Syndrome (IBS). The symptoms of functional disorders such
Continue Reading